Sign inThe pharma-technology company completed its purchase of automotive supplier Dura Driver Control Systems on August 6, 2026, adding over $200 million in reported 2025 revenue.
SEC filing
The trial hit all Week 16 endpoints for the 60 mg sonelokimab arm, and MoonLake says it has cash into mid-2028.
SEC filing
The company will not advance SION-719 as an add-on to standard of care, while a separate Phase 1 trial identified SION-451 plus SION-2222 as its preferred dual combination.
SEC filing
Amneal paid $375 million in cash plus 28.9 million shares, with up to $350 million in milestone payments and royalties tied to the deal.
SEC filing
The company said study results support a planned third-quarter 2026 resubmission of its epinephrine sublingual film NDA after a January 2026 FDA rejection.
SEC filing
The company said the IND for Lucid-21-302 was cleared on Aug. 10, 2026, opening the way for a randomized, double-blind, placebo-controlled trial in progressive multiple sclerosis.
SEC filing
The antibody hit its primary endpoints in a placebo-controlled trial, cutting hot flash frequency and severity after one dose.
SEC filing (3)
The SANRECO trial hit its primary and secondary endpoints, and Silence plans a Phase 3 study in the first half of 2027.
SEC filing
The company reported roughly $237 million in cash and outlined progress across its four radiopharmaceutical programs ahead of a planned Phase 3 trial in neuroendocrine tumors.
SEC filing
The deal, signed August 10, 2026, centers on epilepsy drug candidate ABS-1230 and includes milestone payments tied to regulatory approval and sales targets.
SEC filing
Subgroup analyses showed benefit in sicker patients, and the company plans to seek an FDA meeting to discuss adjusting the registrational program.
SEC filing
The deal adds ABS-1230, a precision therapy for KCNT1+ epilepsy, plus up to $500 million in contingent milestones.
SEC filing
Sobi will pay $75 million upfront and could owe up to $505 million more as Innate begins a Phase 3 trial toward accelerated approval in Sézary syndrome.
SEC filing
Sana said it expects an SC451 IND filing and Phase 1/2 start this year, alongside first-in-human SG293 data, with cash runway into mid-2027.
SEC filing
The company disclosed an FDA Additional Information Request tied to its transplant test kit and reported a Q2 2026 net loss of $11.3 million.
SEC filing
The company finished dosing all patients in the Phase 2 SANRECO trial for divesiran and reported $72.1 million in cash as of June 30, 2026.
SEC filing
The company reported second-quarter 2026 results, an FDA feedback session on NEO212, and cash of $2.0 million alongside undrawn credit facilities.
SEC filing
The company says it is now positioned for topline eGFR slope results in Q2 2027, with cash reported at $181.6 million as of June 30, 2026.
SEC filing
AIM says it finished enrollment and dosing in its Phase 2 pancreatic cancer study and expects survival data in 2027, while cash rose to $9.9 million.
SEC filing
Zelicapavir advances in both pediatric and adult RSV programs while Enanta guides cash runway into fiscal 2029.
SEC filing
DiaMedica completed its first fetal growth restriction cohort and detailed next steps for its preeclampsia program, while reporting $43.5 million in cash.
SEC filing
The appointment, effective August 6, 2026, was disclosed in an 8-K filed after an August 3 board action.
SEC filing
The New Haven biopharma's registration statement covers shares tied to a May 2026 private placement and pre-IPO preferred stock rounds, with no proceeds going to the company from most sales.
SEC filing
The clinical-stage pain drug developer sold 19.2 million shares to raise about $315.7 million in net proceeds ahead of an August 10, 2026 closing.
SEC filing
The company's August 5, 2026 filing confirms his departure was immediate, with no successor named in the disclosure.
SEC filing
ANI reported 25.9% revenue growth to $266 million and reaffirmed full-year guidance while narrowing its Cortrophin Gel sales range for 2026.
SEC filing
The appointment, disclosed in an 8-K/A, comes about four months after Pavao joined Coya's board in April 2026.
SEC filing
Dane Stevens acquired the shares at CDN$6.70 apiece on August 5, 2026, using an entity he controls.
SEC filing
A Form 6-K filed August 7, 2026 details the Customer Investment Agreement and guarantee backing IM8's growth spending, along with risk factors tied to the arrangement.
SEC filing
Corbus set up a sale agreement with Jefferies LLC on August 7, 2026, allowing it to sell shares periodically to fund CRB-701 and CRB-913 development.
SEC filing
The Woburn, Mass. biospecimen marketplace company closed the offering on August 7, 2026, after pricing it at $1.30 per share.
SEC filing (2)
China's CDE accepted the NDA for hydronidone in liver fibrosis and Gyre started a new lung injury trial, while the company affirmed its full-year revenue guidance.
SEC filing
Dr. Barbara Weber's employment as Executive Chair ended August 3, 2026, and Tango filed an 8-K/A on August 7 detailing the severance terms of her exit.
SEC filing (2)
Neogen disclosed in an 8-K that director Thierry Bernard left the board effective August 3, 2026.
SEC filing
The Delaware biotech reported one investor and $200,000 raised through a Simple Agreement for Future Equity, in a notice signed August 7, 2026.
SEC filing
Minerva said its confirmatory Phase 3 trial of roluperidone remains on track, with Phase A topline data expected in the second half of 2027 and Phase B data in the second half of 2028.
SEC filing
Kiora moved both retinal disease programs into higher-dose enrollment and said cash on hand should fund operations into late 2028.
SEC filing
The company is awaiting FDA feedback by late August 2026 on its planned Phase 3 pulmonary sarcoidosis trial while restructuring to preserve cash into late 2028.
SEC filing
The company said its longitudinal clinical trial has begun enrolling patients at 11 sites while cash fell to $2.4 million as of June 30, 2026.
SEC filing
Atossa Therapeutics said enrollment finished in its Phase 2 breast cancer trial of (Z)-endoxifen and raised up to $16.5 million in a registered direct offering.
SEC filing
Xenetic said its DNase platform advanced through outside research partnerships in the quarter, including a partner-run study clearance in Israel, while cash fell to $6.5 million.
SEC filing
VolitionRx reported in an 8-K signed August 7, 2026 that it issued shares to Lind Global Asset Management XII LLC to meet payment and conversion terms tied to earlier convertible notes.
SEC filing
The former Avalon GloboCare, renamed in July 2026, disclosed a $10 million equity line, going-concern doubts, and a new drone-defense subsidiary alongside its AI and Keto Air businesses.
SEC filing (2)